PT 141

Descripción

• Physical profile: Lyophilized powder
• This product is sold as a research chemical and not for human or animal consumption. For laboratory use by qualified professionals.

  PT-141 10mg IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

  Additional Information

  Buy PT-141 10mg Research Peptide Online

  PT-141 10mg Product Specifications & Storage

  Bremelanotide functions as a synthetic cyclic nonapeptide engineered to demonstrate melanocortin receptor selectivity across multiple isoforms. This compound has garnered significant preclinical attention due to its dual-action profile on melanocortin-3 and melanocortin-4 receptors, with secondary affinity for melanocortin-1 receptors. Structural design employs cyclic peptide architecture to enhance binding specificity and metabolic stability compared to linear melanocortin analogs.

  PT-141 Mechanism of Action

  The mechanism involves direct agonism at melanocortin receptor subtypes expressed throughout the central and peripheral nervous systems. In rodent models, MC3R and MC4R activation triggers distinct intracellular cascades including adenylyl cyclase elevation and cyclic adenosine monophosphate (cAMP) accumulation. These pathways regulate multiple physiological processes studied in preclinical neuroscience research.

  PT-141 Published Research Summary

  Peer-reviewed literature including Journal of Medicinal Chemistry publications document bremelanotide’s receptor binding kinetics, selectivity profiles, and cellular signaling characteristics. Animal studies conducted using transgenic mice demonstrate melanocortin pathway involvement in homeostatic regulation. Preclinical investigations establish pharmacokinetic parameters and tissue distribution patterns distinct from natural melanocyte-stimulating hormone.

  Research examining melanocortin agonists in vitro demonstrates receptor-specific activation through radioligand binding assays and electrophysiology recordings. Studies published by the National Institutes of Health research programs detail molecular interaction profiles and second-messenger system activation.

  This peptide is supplied as 10mg lyophilized powder for subcutaneous or intravenous administration in research models. Reconstitution requires sterile water or 0.9% bacteriostatic saline. Reconstituted solutions maintain stability for 48 hours at 2-8°C under sterile conditions.

  DISCLAIMER: This product is supplied exclusively for research and preclinical investigation. Not intended for human consumption, therapeutic use, or any medical application. All claims reflect published peer-reviewed research conducted in animal models only. Users must comply with institutional guidelines and applicable regulations.

  Protocol

  Clinical Research